Background Impairment in a wide range of cognitive abilities has been consistently reported
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …

Objective. To review the clinical usefulness of N‐acetylcysteine (NAC) as treatment or
adjunctive therapy in a number of medical conditions. Use in Tylenol overdose, cystic …

Objectives The therapeutic use of nutrient-based 'nutraceuticals' and plant-based
'phytoceuticals' for the treatment of mental disorders is common; however, despite recent …

Dopamine (DA) is a major monoamine neurotransmitter in the brain and has essential roles
in higher functions of the brain. Malfunctions of dopaminergic signaling have been …

Schizophrenia is recognized to be a highly heterogeneous disease at various levels, from
genetics to clinical manifestations and treatment sensitivity. This heterogeneity is also …

Schizophrenia is associated with increased levels of oxidative stress, as reflected by an
increase in the concentrations of damaging reactive species and a reduction in anti-oxidant …

A growing body of evidence has emerged demonstrating a pathological link between
oxidative stress and schizophrenia. This evidence identifies oxidative stress as a …

Abstract N-acetyl-L-cysteine (NAC) is a compound of increasing interest in the treatment of
psychiatric disorders. Primarily through its antioxidant, anti-inflammatory, and glutamate …

Despite strong evidence of the neurodevelopmental origins of psychosis, current
pharmacological treatment is not usually initiated until after a clinical diagnosis is made, and …

Research into the neurobiological processes that may lead to the onset of schizophrenia
places growing emphasis on the glutamatergic system and brain development. Preclinical …